PODD - candlestick chart analysis of Insulet Corporation

PODD News
28-Aug-2024 12:35 AM CST - Business Insider Insulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5 Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on Insulet (PODD - Research Report) and keeping the price target at
27-Aug-2024 4:59 PM CST - Business Insider Insulet's Omnipod 5 Automated Insulin Delivery System Receives FDA Clearance For Type 2 Diabetes Insulet Corp. (PODD) has just received the green light from the U.S. Food and Drug Administration for its groundbreaking SmartAdjust
27-Aug-2024 11:48 AM CST - Investopedia Top Stock Movers Now: Nvidia, Insulet, Paramount Global, and More Nvidia shares advanced after Truist raised its price target on the stock. Edgar Bronfman Jr. dropped his bid ... citing improving fundamentals and "sentimental" factors. Shares of Insulet (PODD) jumped when the Food and Drug Administration (FDA) approved ...
27-Aug-2024 10:11 AM CST - MarketWatch Insulet Shares Rise as FDA Clears Omnipod 5 for Type 2 Diabetes Patients Insulet's stock rose Tuesday morning after the company's automated insulin delivery system was cleared by the Food and Drug Administration for people with type 2 diabetes. Shares climbed 7.5% to $194.19 in recent trading. The stock is down about 10% this year.
27-Aug-2024 5:53 AM CST - Yahoo Finance Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes Insulet Corp.'s PODD groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k ...
27-Aug-2024 12:15 AM CST - Business Insider TD Cowen Keeps Their Buy Rating on Insulet (PODD) However, on August 12, Barclays maintained a Hold rating on Insulet (NASDAQ: PODD). Based on Insulet's latest earnings ... corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders ...
26-Aug-2024 11:32 PM CST - Business Insider Insulet's Omnipod 5 Expansion into Type 2 Diabetes Market: A Strong Buy Rating BTIG analyst Marie Thibault has reiterated their bullish stance on PODD stock, giving a Buy rating today. Marie Thibault's rating is based on a few key developments surrounding Insulet's Omnipod 5 (O5) system. The U.S. Food and Drug Administration (FDA ...
21-Aug-2024 6:15 AM CST - Business Insider Insulet (PODD) Gets a Buy from TD Cowen TD Cowen analyst Josh Jennings maintained a Buy rating on Insulet (PODD - Research Report) today and set a price target of $264.00. The

◄ Daily Pattern ►

Bullish Harami

21-Aug-2024

-6.2 strength

PODD News

28-Aug-2024 12:35 AM CST - Business Insider
Insulet Stock Buy Rating: FDA Approval Expands Market Reach for Omnipod 5
Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on Insulet (PODD - Research Report) and keeping the price target at

27-Aug-2024 4:59 PM CST - Business Insider
Insulet's Omnipod 5 Automated Insulin Delivery System Receives FDA Clearance For Type 2 Diabetes
Insulet Corp. (PODD) has just received the green light from the U.S. Food and Drug Administration for its groundbreaking SmartAdjust

27-Aug-2024 11:48 AM CST - Investopedia
Top Stock Movers Now: Nvidia, Insulet, Paramount Global, and More
Nvidia shares advanced after Truist raised its price target on the stock. Edgar Bronfman Jr. dropped his bid ... citing improving fundamentals and "sentimental" factors. Shares of Insulet (PODD) jumped when the Food and Drug Administration (FDA) approved ...

27-Aug-2024 10:11 AM CST - MarketWatch
Insulet Shares Rise as FDA Clears Omnipod 5 for Type 2 Diabetes Patients
Insulet's stock rose Tuesday morning after the company's automated insulin delivery system was cleared by the Food and Drug Administration for people with type 2 diabetes. Shares climbed 7.5% to $194.19 in recent trading. The stock is down about 10% this year.

27-Aug-2024 5:53 AM CST - Yahoo Finance
Insulet's Omnipod 5 Wins FDA Approval for Type 2 Diabetes
Insulet Corp.'s PODD groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k ...

27-Aug-2024 12:15 AM CST - Business Insider
TD Cowen Keeps Their Buy Rating on Insulet (PODD)
However, on August 12, Barclays maintained a Hold rating on Insulet (NASDAQ: PODD). Based on Insulet's latest earnings ... corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders ...

26-Aug-2024 11:32 PM CST - Business Insider
Insulet's Omnipod 5 Expansion into Type 2 Diabetes Market: A Strong Buy Rating
BTIG analyst Marie Thibault has reiterated their bullish stance on PODD stock, giving a Buy rating today. Marie Thibault's rating is based on a few key developments surrounding Insulet's Omnipod 5 (O5) system. The U.S. Food and Drug Administration (FDA ...

21-Aug-2024 6:15 AM CST - Business Insider
Insulet (PODD) Gets a Buy from TD Cowen
TD Cowen analyst Josh Jennings maintained a Buy rating on Insulet (PODD - Research Report) today and set a price target of $264.00. The

HotCandlestick Free Newsletter

Insulet Corporation

Candlestick stock chart pattern and Fibonacci retracement analysis for PODD

Insulet Corporation

HotCandlestick

Free Newsletter